Liron Rozenfeld
About Liron Rozenfeld
Liron Rozenfeld is a Senior Finance Controller at Kite Pharma, with extensive experience in finance roles across various companies in Europe. He has a strong background in financial management and expertise in engineered cell therapies.
Work at Kite Pharma
Liron Rozenfeld serves as the Senior Finance Controller at Kite Pharma, a Gilead Company, since 2020. In this role, he focuses on driving data integrity and compliance within Kite Pharma's European operations. He has played a key role in building finance capabilities to support various functions including European Manufacturing, Quality, Supply Chain, and General & Administrative (G&A) functions.
Previous Experience in Finance
Before joining Kite Pharma, Liron Rozenfeld held several finance-related positions. He worked at Uber as Senior Manager Finance, Strategy & Global Transformation from 2018 to 2020. Prior to that, he was employed at Mead Johnson Nutrition as Finance Shared Service Manager – Europe from 2010 to 2018, and as Finance Controller - Europe from 2016 to 2018. His earlier roles include Regional Finance Controller/Finance Director at Atlas Air from 2003 to 2007, and Regional Accountant (Interim) at Belkin in 2008.
Education and Expertise
Liron Rozenfeld has a strong educational background in business administration and finance. He earned a Bachelor of Business Administration (BBA) from Delta University, studying from 1995 to 1998. He furthered his education with a Master of Business Administration (MBA) from The University of Sheffield, completing his studies from 1998 to 2000. Additionally, he studied at Motorola University in Dubai, UAE, where he achieved a Green Belt in Six Sigma in 2005.
Specialized Knowledge in Cell Therapies
Liron Rozenfeld possesses expertise in financial aspects of chimeric antigen receptor (CAR) and T cell receptor (TCR) engineered cell therapies. This specialized knowledge supports his role in the biotech industry, particularly in managing financial operations related to advanced therapeutic areas at Kite Pharma.